Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Silk Fibroin-Based Coatings for Pancreatin-Dependent Drug Delivery

Silk Fibroin-Based Coatings for Pancreatin-Dependent Drug Delivery

Thumbnail Image
Download
Name

nihms-1962419.pdf

Size

1.04 MB

Format

Adobe PDF

Checksum (MD5)

eaf99885f69a39b4d1ce81441eef9891

sword-2024-07-03T15:44:49.original.xml (130 B)
Original SWORD entry document
Author(s)
Navamajiti, Natsuda
•
Gardner, Apolonia
•
Cao, Ruonan
•
Sugimoto, Yutaro
•
Yang, Jee Won
•
Lopes, Aaron
•
Phan, Nhi V.
•
Collins, Joy
•
Hua, Tiffany
•
Damrongsakkul, Siriporn
more
Date Issued
March 2024
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Citation
Navamajiti, Natsuda, Gardner, Apolonia, Cao, Ruonan, Sugimoto, Yutaro, Yang, Jee Won et al. 2024. "Silk Fibroin-Based Coatings for Pancreatin-Dependent Drug Delivery." Journal of Pharmaceutical Sciences, 113 (3).
Version
Author's final manuscript
Abstract
Triggerable coatings, such as pH-responsive polymethacrylate copolymers, can be used to protect the active pharmaceutical ingredients contained within oral solid dosage forms from the acidic gastric environment and to facilitate drug delivery directly to the intestine. However, gastrointestinal pH can be highly variable, which can reduce delivery efficiency when using pH-responsive drug delivery technologies. We hypothesized that biomaterials susceptible to proteolysis could be used in combination with other triggerable polymers to develop novel enteric coatings. Bioinformatic analysis suggested that silk fibroin is selectively degradable by enzymes in the small intestine, including chymotrypsin, but resilient to gastric pepsin. Based on the analysis, we developed a silk fibroin-polymethacrylate copolymer coating for oral dosage forms. In vitro and in vivo studies demonstrated that capsules coated with this novel silk fibroin formulation enable pancreatin-dependent drug release. We believe that this novel formulation and extensions thereof have the potential to produce more effective and personalized oral drug delivery systems for vulnerable populations including patients that have impaired and highly variable intestinal physiology.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-ShareAlike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/155443
DOI of Published Version
https://doi.org/10.1016/j.xphs.2023.09.001
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.